Multiple Myeloma in HUSM. Dr Azlan Husin HUSM
|
|
- Matilda Harrington
- 8 years ago
- Views:
Transcription
1 Multiple Myeloma in HUSM Dr Azlan Husin HUSM
2 Outline Overview Presenting features Progress in myeloma Global HUSM
3 Multiple myeloma is a neoplastic plasma-cell disorder that is characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, associated organ dysfunction
4 MGUS Smouldering - MM
5
6 Pathology of Myeloma Skeletal destruction Hypercalcaemia Spinal cord compression Fractures Marrow Infiltration Anaemia Thrombocytopenia Neutropenia Myeloma protein Renal damage Hyperviscosity Bleeding Amyloidosis Malignant proliferation of plasma cells Immune paresis Recurrent infections Poor humoral immunity
7 Criteria for Diagnosis of MM MM* (all 3 criteria required) Monoclonal plasma cells in bone marrow 10% and/or presence of biopsy-proven plasmacytoma Monoclonal protein present in serum and/or urine Myeloma-related organ dysfunction (1 or more) (C) Calcium elevation in blood (serum calcium >2.88 mmol/l or ULN) (R) Renal insufficiency (secr > 177 µmol/l) (A) Anemia (hemoglobin <10 g/dl or 2g <normal) (B) Lytic bone lesions or osteoporosis ** *Note: These criteria identify Stage IB and Stages II and III A/B myeloma by Durie/Salmon stage. Stage IA becomes smoldering or indolent myeloma; If no monoclonal protein is detected (non-secretory disease), then 30% monoclonal bone marrow plasma cells and/or a biopsy-proven plasmacytoma required; A variety of other types of end organ dysfunctions can occasionally occur and lead to a need for therapy. Such dysfunction is sufficient to support classification as myeloma if proven to be myeloma related; **If a solitary (biopsy-proven) plasmacytoma or osteoporosis alone (without fractures) are sole defining criteria, then 30% plasma cells are required in BM Durie BGM et al. Hematol J. 2003;4:379 [published correction in Hematol J. 2004;5:285] Kyle RA et al. Mayo Clin Proc. 2003;78:21
8 Durie-Salmon Staging Stage Criteria Myeloma Cell Mass ( cells/m 2 ) I All of the following: Hemoglobin >10 g/dl Serum calcium level <10.5 mg/dl (normal) Normal bone or solitary plasmacytoma on X ray Low M-component production rate: IgG <5 g/dl; IgA <3 g/dl Bence Jones protein <4 g/24 hr Median OS (months) <0.6 (low) 82 II Not fitting stage I or III (intermediate) 68 III One or more of the following: Hemoglobin <8.5 g/dl Serum calcium level >12 mg/dl Advanced lytic bone lesions on X ray High M-component production rate: IgG >7 g/dl; IgA >5 g/dl Bence Jones protein >12 g/24hr >1.2 (high) 50 Subclassification A B Criteria Normal renal function (serum creatinine level <177 micmol/l) Abnormal renal function (serum creatinine level 177 micmol/l) Durie BG, Salmon SE. Cancer. 1975;36:842 Multiple Myeloma Research Foundation. Available at:
9 International Staging System Stage Criteria Median OS I Serum 2 M <3.5 mg/l Serum albumin 3.5 g/dl 62 mo II Serum 2 M <3.5 mg/l 44 mo Serum albumin <3.5 g/dl OR Serum 2 M 3.5 to <5.5 mg/l* III Serum 2 M 5.5 mg/l 29 mo *Irrespective of serum albumin level Greipp PR et al. J Clin Oncol. 2005;23:3412
10 Prognostic markers Clinical Durie-Salmon IIIB ISS stage I vs III LDH Normal vs high β2-m Low/normal vs high Cytogenetic Conventional del 13 hypodiploidy FISH t(11;14) t(4;14) del 17p13
11
12 Percentage ISS: Survival Median Deaths/N in Months Stage I 606/ (58,65) Stage II 1054/ (42,45) Stage III 968/ (26,32) Months From Initial Chemotherapy Treatment Greipp PR et al. J Clin Oncol. 2005;23:3412
13 PROGRESS IN TREATMENT
14 Principal management To eradicate myeloma cells? Cure Induction Consolidation High dose chemo + auto SCT Maintenance Supportive therapy Bone disease: Pain, fracture management, bisphosphonate, surgery, radiotherapy, analgesics Anemia: Transfusion, erythropoietin Renal support Infection prevention Thrombosis prevention
15 Treatment Options in Multiple Myeloma 1990s Supportive care (AB, Vaccination, Erythropoetin) 1962 Melphalan/ Prednisone 1999 Thalidomide 2002 modif. allo-sct 2006 Lenalidomide Melphalan Since 1990s Myeloablation + ASCT 2000s Tandem ASCT 2003/2004 Bortezomib
16 Thalidomide & Lenalidomide 1950 s 1970 s 1960 s
17 Thalidomide & Lenalidomide Proposed MOA Inhibit IL-6 production Activation of apoptotic pathways Activation of T cells to produce IL-2 augmenting the activity of NKdependent cytotoxicity. Side effect Sedation, peripheral neuropathy, constipation, DVT, marrow suppression More potent than thalidomide No or minimal neuropathy More incidence marrow suppression than thalidomide Others s/e same: DVT, teratogenicity
18 Proteosome inhibition
19 Induction / Consolidation / Maintenance CTD CyBORD Thalidomide TD VMP Lenalidomide VTD MPT Velcade VMP VAD VT VD ESHAP RD or Rd dvd RVD PAD MPR VMPT MP DT-PACE VcTD
20 Soup of abbreviated alphabets
21 Treatment approach: Old Paradigm Induction Chemotherapy Transplant Nonalkylating Agent No Transplant Alkylating Agent Induction chemotherapy choice depends on transplant status Transplant candidates induced with nonalkylating agents Nontransplant candidates treated with alkylating agents Depth of response to induction therapy Not critical in transplant CR, PR, or SD acceptable Kyle RA, et al. N Engl J Med. 2004;351:
22 Induction Therapy :Traditional Study N Regimen CR/ ncr CR + PR Stem Cell Harvest Rajkumar 100 Dex 0% 50% Yes Goldschmidt 203 VAD 3% 63% Yes Rifkin 97 DVd 3% 43% Yes IFM VMCP/ BVAP 5% 52% Yes/No Palumbo 126 MP 7% 48% No Ref JCO 2006 ASH 2005 Cancer 2006 NEJM 1996 ASH 2005 DVd, liposomal doxorubicin, vincristine, dexamethasone; VMCP/BVAP, vincristine, melphalan, cyclophosphamide, prednisone, carmustine, and doxorubicin.
23 Treatment approach: New Paradigm Induction Novel Agents Transplant No Transplant Start induction therapy with novel agents Aim for CR or PR May improve efficacy in nontransplant candidates May make stem cell transplant optional May allow transplant decision to be deferred If indicated, may optimize stem cell transplantation
24 Treatment strategy in myeloma
25 IMWG uniform criteria
26 IMWG uniform criteria
27 Treatment strategy in myeloma
28 AK Stewart, PG Richardson and JF San-Miguel, Blood 2009
29
30
31
32
33 IMWG uniform criteria for survival PFS: Progression Free Survival PFS is the time from start of the treatment to disease progression or death. This encompasses all patients and has been considered a surrogate marker for overall survival duration. EFS: Event-free survival The definition depends on how event is defined. In some studies, this can be the same as PFS. EFS can also include additional events that are considered to be of importance besides death, including serious drug toxicity. EFS is not recommended for general use unless specifically defined, as confusion can arise about the details of additional events
34 IMWG uniform criteria for survival TTP: Time to Progression time from start of treatment to disease progression with deaths owing to causes other than progression not counted, but censored. This is a helpful method to assess the durability of treatment benefit. DFS: Disease-free survival applies to patients in CR, and is measured from the start of CR to the time of relapse from CR. limited value in myeloma at present. OS: Overall survival Over 5 years of follow-up are required to assess benefit. Initial response and TTP may or may not translate into overall survival benefit.
35 IMWG uniform criteria for survival DOR: Duration of Response applies to patients achieving at least PR by and is measured from start of achieving PR (first observation of PR before confirmation) to the time of disease progression, with deaths owing to causes other than progression not counted, but censored. for consideration in the assessment of new agents and/or new comprehensive treatment strategies
36 Treatment strategy in myeloma
37
38
39
40
41
42 Maintenance Rx in elderly?
43
44
45
46 Novel agents Good side Can be treated as outpatient / daycare Remarkable efficacy esp in combination Response after induction Improved response after HSCT Improved in PFS, TFS Trend towards improving OS Bad side Peripheral neuropathy Thalidomide Bortezomib Thrombotic events Thalidomide, Lenalidomide Myelosupression Lenalidomide, thalidomide Bortezomib (mild, plt) Infection Lenalidomide, thalidomide Bortezomib (mild, plt) Others GI upset, sedation
47 Most important complication 21 caps, 25 mg, 26 thousand RM!
48 Most important complication 1 vial, 3.5 mg, 3 thousand++ RM! Need 4 vials / cycle
49 Most important complication 1 box, 100 mg, 28 tablets, 2 hundreds RM! Need 4 vials / cycle
50 WHY HIGH DOSE CHEMO & AUTO SCT?
51
52 Principle of HD chemo & auto SCT Giving myoablative chemotherapy / radiotherapy Followed by re-infusion of patient s hemopoietic stem cells (as rescue) That was collected via apharesis technique Stored in nitrogen storage
53 Auto SCT in HUSM First patient started in November 2007 Offered for upfront Rx for myeloma patient age 70 or less Upfront Rx for selected high risk aggressive NHL / HL Consolidation Rx for patient with relapse NHL/HL?? Patients so far No TRM
54 Preparation for transplant Patient has to undergo induction Rx to achieve CR or VGPR Hemopoieitic stem cell mobilization High dose cylophosphamide + GCSF Hemopoieitic stem cell collection BM harvest Peripheral Blood Stem Cell Collection
55
56
57
58
59 Treatment strategy in myeloma
60 Lower relapse rate following exposure to drugs
61 Auto SCT in HUSM
62 Supportive / adjunct therapy Myeloma bone disease Bisphosphonate (Pamidronate / Zolendronate) Pain Caution in renal impairment, infusion rate Osteonecrosis of the jaw (dental team) Good analgesic : opioid based constipation/dizzy/stigma Fracture Cord compression Radiation therapy Spine team : surgery / vetebroplasty / kyphoplasty
63
64 Osteonecrosis of the jaw
65 Supportive / adjunct therapy Anemia Blood transfusion Look for other cause: GIB Erythropoietin Selected patient, target of Hb Concerns Renal support Hydration / Hemodialysis / Plasmapharesis Avoid nephrotoxic (ACE-I, ARB, NSAIDs)
66
67 Supportive / adjunct therapy Infection: Disease + treatment associated IV IgG support 0.4g/kg/dose every 3-4 weeks Antimicrobial prophylaxis Bactrim, Acyclovir, +/- fluconazole
68 Supportive / adjunct therapy Prevention of thrombotic event According to risk profile: mobility, treatment use Non pharmacological measure Hydration Elastic stocking Physiotherapy Aspirin / warfarin / LMWH / pentasaccharide (fondaparinux)
69 PROGRESS IN SURVIVAL
70 10-year relative survival (%) Improvements in survival of younger patients Period estimates of 10-yr survival by major age groups in defined calendar periods Calendar period < Brenner et al. Blood 2008
71 Myeloma patients treated in HUSM Presenting Sx Duration of Sx Treatment Survival Total 58 Bone pain 39/53 (73.6%) Cord / nerve compression 8/40 (20%) Anemia 28/41 (68.3%) Renal impairment 14/41 (34.1%) Hyper Ca 17/35 (48.6%) Recurr infection 8/43 (18.6%) Mass 10/43 (23.2%) Analyzable= 50 Before 2005 VAD MP Dex Pred Analyzable = 35 pt > 3 mo = 62.5% Median = 22 mo After 2005 TD Td VD VTD RVD 2 years = 29.30% 3 years = 24.13% Current status 24 / 52 alive
72 Consideration Treatment efficacy Treatment toxicity
73 THANK YOU Audience Committee members MOs & supporting staffs in Hemato/ Onco wards HUSM AVA & security staffs Department of Medicine, SMS USM IMS- USM Roche (M)
74 SAFE JOURNEY BACK HOME
MULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology
MULTIPLE MYELOMA Review & Update for Primary Care Dr. Joseph Mignone 21st Century Oncology OVERVIEW Identify the diagnostic criteria for multiple myeloma Compare first & second line therapies, using data
More informationMultiple Myeloma Patient s Booklet
1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore 119228 Email : ncis@nuhs.edu.sg Website : www.ncis.com.sg LIKE US ON FACEBOOK www.facebook.com/ nationaluniversitycancerinstitutesingapore Multiple
More informationCurrent Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
More informationOutline. Question 1. Question 2. What is Multiple Myeloma? Andrew Eisenberger, MD
Outline A Disease Overview June 3, 2013 Andrew Eisenberger, MD Assistant Professor of Medicine Hematology/Oncology Columbia Presbyterian Medical Center Introduction Epidemiology/Risk Factors Clinical Features/Diagnostic
More informationTreating myeloma. Dr Rachel Hall Royal Bournemouth Hospital
Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens
More informationThings You Don t Want to Miss in Multiple Myeloma
Things You Don t Want to Miss in Multiple Myeloma Sreenivasa Chandana, MD, PhD Attending Hematologist and Medical Oncologist West Michigan Cancer Center Assistant Professor, Western Michigan University
More informationTreatment results with Bortezomib in multiple myeloma
Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of
More informationMultiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma.
Multiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma. The intent is to positively identify patients with active or
More informationA Clinical Primer. for Managed Care Stakeholders
reviews therapy Diagnosing, Staging, and Treating Multiple Myeloma: A Clinical Primer for Managed Care Stakeholders by Ralph V. Boccia, MD, FACP, Medical Director, Center for Cancer and Blood Disorders
More informationMultiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, 2008. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida
Multiple Myeloma: Novel Agents Robert A. Kyle, M.D. Germany June 28, 2008 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Multiple Myeloma Untreated Initial Therapy Transplant eligible Multiple
More informationUNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
More informationCure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
More informationSTEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationFEIST- WEILLER CANCER CENTER MULTIPLE MYELOMA GUIDELINES. Updated December, 2011. Authors: Nebu Koshy, MD. Binu Nair, MD. Gerhard Hildebrandt, MD
FEIST- WEILLER CANCER CENTER MULTIPLE MYELOMA GUIDELINES Updated December, 2011 Authors: Nebu Koshy, MD Binu Nair, MD Gerhard Hildebrandt, MD Reinhold Munker, MD Glenn Mills, MD Mandatory initial tests
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationMultiple Myeloma Workshop- Tandem 2014
Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone
More informationMultiple Myeloma and Amyloidosis: Optimism for Heretofore Incurable Diseases
Multiple Myeloma and Amyloidosis: Optimism for Heretofore Incurable Diseases Robert Vescio, MD Director Multiple Myeloma & Bone Metastases Program Samuel Oschin Comprehensive Cancer Center Cedars-Sinai
More informationMULTIPLE MYELOMA 1 PLASMA CELL DISORDERS Multiple l Myeloma Monoclonal Gammopathy of Undetermined Significance (MGUS) Smoldering Multiple Myeloma (SMM) Solitary Plasmacytoma Waldenstrom s Macroglobulinemia
More informationMultiple. Powerful thinking advances the cure
Multiple Myeloma Treatment OVERVIEW Powerful thinking advances the cure Powerful thinking advances the cure About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation (MMRF)
More informationMultiple Myeloma Making Sense of the Report Forms. Parameswaran Hari Medical College of Wisconsin Milwaukee
Hodgkin CML MDS/Other Leuk CLL Neuroblastoma Multiple Myeloma Making Sense of the Report Forms Parameswaran Hari Medical College of Wisconsin Milwaukee Indications for Blood and Marrow Transplantation
More informationMULTIPLE MYELOMA Treatment Overview
MULTIPLE MYELOMA Treatment Overview ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION After being diagnosed with multiple myeloma in 1998, Kathy Giusti and her sister Karen Andrews, a successful corporate
More informationMULTIPLE MYELOMA. Version Date: February, 2015
MULTIPLE MYELOMA Version Date: February, 2015 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team synthesis of currently accepted approaches
More informationAdvances in multiple myeloma
Oncology 295 Advances in multiple myeloma Multiple myeloma is a malignant disease characterised by a clonal population of plasma cells in the bone marrow. The disease occurs in the elderly and results
More informationProtocol for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat: MULTIPLE MYELOMA
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: MULTIPLE MYELOMA Patient information given at each stage following agreed information
More informationBackground Information Myeloma
Myeloma FAST FACTS Myeloma, also known as multiple myeloma, is a type of cancer that develops from plasma cells which originate in the bone marrow 1 Myeloma is the second most common type of blood cancer
More informationMultiple Myeloma. Solving a growing puzzle
Multiple Myeloma Solving a growing puzzle Disclosures Financial I wish. I eat too much. I did ask who the audience would be. Nurses and Doctors Goals 1. Understand the incidence, symptoms, and pathophysiology
More informationBone Disease in Myeloma
Bone Disease in Myeloma Washington, DC August 8, 2009 Brian G.M. Durie, M.D. Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma Vascular Cytokines
More informationNew diagnostic criteria for myeloma
New diagnostic criteria for myeloma Dr Guy Pratt Senior Lecturer/Honorary Consultant Haematologist University of Birmingham/Heart of England NHS Trust International Myeloma Working Group (IMWG) define
More informationTABLE OF CONTENTS. Multiple Myeloma / Plasma Cell Leukemia Pre-HSCT Data
Instructions for Multiple Myeloma / Plasma Cell Leukemia Pre-HSCT Data (Form 2016) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Multiple Myeloma /
More informationBone Disease in Myeloma. St. Petersburg, Russia September 16, 2009
Bone Disease in Myeloma St. Petersburg, Russia September 16, 2009 Bi Brian G.M. GMDurie, M.D. MD Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma
More informationI've Just Been Diagnosed. with Multiple Myeloma, What s Next?
I've Just Been Diagnosed with Multiple Myeloma, What s Next? Table of Contents Message from a Survivor Introduction What is Multiple Myeloma? What Causes Multiple Myeloma? Genes & Multiple Myeloma What
More informationMultiple Myeloma Therapy Doublet, Triplet, and beyond October 2013 The IV. International Eurasian Congress of Hematology Rafat Abonour, M.D.
Multiple Myeloma Therapy Doublet, Triplet, and beyond October 2013 The IV. International Eurasian Congress of Hematology Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm,
More informationShaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological
An update on the management of multiple myeloma and amyloidosis Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological malignancy in this country affecting nearly
More informationMyeloma pathways to diagnosis UCLP audit
Myeloma pathways to diagnosis UCLP audit Dr Neil Rabin Consultant Haematologist University College London Hospitals & North Middlesex University Hospital Myeloma Clinical Features Bone pain (70%) High
More informationThe following investigations are required at diagnosis, so that a disease category and stage can be assigned (see below).
3 MULTIPLE MYELOMA Clinical features Multiple myeloma (MM) is a disease with a peak incidence in the 6 th and seventh decades of life, but can also occur in younger patients. It is characterised by infiltration
More informationThe Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline
The Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline Introduction ASCO convened an Update Committee to review and update the 2002 recommendations for the role of bisphosphonates
More informationBone Disease in Myeloma
Bone Disease in Myeloma Boston, Massachusetts Saturday, July 26, 2008 Brian G.M. Durie, M.D. Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma
More informationWhole Antibody and Free Light Chain Production by Plasma Cells
MYELOMA Very Good ; Stringent or Complete Navigating the maze of Responses Parameswaran Hari Medical College of Wisconsin Milwaukee Increasing understanding of disease biology in the last few years Deeper
More informationA Science Writer s Guide to Multiple Myeloma
A Science Writer s Guide to Multiple Myeloma 1 A Science Writer s Guide to Multiple Myeloma A Science Writer s Guide to Multiple Myeloma PREFACE Blood cancers and related disorders a serious health risk
More informationSOUTHWEST ONCOLOGY GROUP CLINICAL RESEARCH ASSOCIATE (CRA) MANUAL. MYELOMA CHAPTER 10 REVISED: March 2008
Introduction This disease site includes the following three malignancies: multiple myeloma, amyloidosis, and waldenstrom's macroglobulinemia. See pages 4 and 5 for descriptions of the latter two diseases.
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More informationMultiple. Powerful thinking advances the cure
Multiple Myeloma DISEASE OVERVIEW Powerful thinking advances the cure Powerful thinking advances the cure About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation (MMRF)
More informationPlasma cell dyscrasias Mark Drayson
Plasma cell dyscrasias Mark Drayson Mortality statistics for England and Wales. Deaths attributed to multiple myeloma from 1988-1997 by age cohort as a percentage of total (21,257) deaths Deaths in age
More informationIntérêt t clinique de l'identification des
Intérêt t clinique de l'identification des chaînes légères l libres Jean-Fran François Lambert Hematologie - CHUV Healthy 69 yo female Negative past medical history 2/07 acute pulmonary edema Progressive
More informationA Diagnostic Chest XRay: Multiple Myeloma
Daniela Marinho Tridente, VI FCMSCSP October 2013 A Diagnostic Chest XRay: Multiple Myeloma Daniela Marinho Tridente, VI FCMSCSP Our Learning Agenda Introduction of our patient His imaging data and findings
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationChapter 2. S. Hovenga 1, J.Th.M. de Wolf 1, J.E.J. Guikema 4, H. Klip 2, J.W. Smit 3, C.Th. Smit Sibinga 5, N.A. Bos 4, E.
Chapter 2 Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses; a high incidence of oligoclonal serum immunoglobulins post transplantation S. Hovenga, J.Th.M. de Wolf, J.E.J.
More informationTreatment of Myeloma Bone Disease
Treatment of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Bone Cancer & Myeloma Research West Hollywood, CA Clinical Consequences of Myeloma Bone Disease Pathological
More informationBendamustine for the fourth-line treatment of multiple myeloma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard
More informationMyeloma. Ann Grace, myeloma survivor. This publication was supported in part by a grant from
Myeloma Ann Grace, myeloma survivor This publication was supported in part by a grant from Revised 2013 A Message From John Walter President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma
More informationCleveland Clinic Taussig Cancer Institute s Multiple Myeloma Program
Cleveland Clinic Taussig Cancer Institute s Multiple Myeloma Program Our mission The primary mission is to provide patients and physicians access to innovative treatment options, medical expertise, and
More informationMultiple Myeloma. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida CP1123175-1
Multiple Myeloma 8 th Annual Living with Myeloma Conference New Developments in Multiple Myeloma Treatment Scottsdale, AZ March 22, 2014 Robert A. Kyle, MD Scottsdale, Arizona Rochester, Minnesota Jacksonville,
More informationMultiple Myeloma Guidelines
Multiple Myeloma Guidelines Approved by Pathway Board for Haematological Malignancies Coordinating author: Dr. Neil Rabin, North Middlesex University Hospital NHST and UCLH Date of issue: 12.03.2015 Version
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More informationLong-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma
ORIGINAL ARTICLE LONG-TERM RESULTS OF REV-DEX THERAPY FOR NEWLY DIAGNOSED MYELOMA Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly
More informationMultiple Myeloma F1 蘇 勇 誠 /MA 林 棟 樑 2007-3-28
Multiple Myeloma F1 蘇 勇 誠 /MA 林 棟 樑 2007-3-28 Plasma Cell Disorders Multiple Myeloma Other Disorders Monoclonal gammopathy of undetermined significance (MGUS) Smoldering multiple myeloma (SMM) Solitary
More informationThe Management of Myeloma & Plasma Cell Disorders
Kent & Medway - Cancer The Management of Myeloma & Plasma Cell Disorders Oncological Treatment Guidelines for the Management of Multiple Myeloma and other Plasma Cell Disorders & Pathway of Care Publication
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007
More informationMULTIPLE MYELOMA. Overview
MULTIPLE MYELOMA Overview Steven R. Schuster, M.D. May 7, 2015 Objectives Give an overview of Multiple Myeloma Everything I know in 15 minutes Explain how genetic information can be used to personalize
More informationSpecial Article. Introduction. Aims. Description of the method used to gather evidence. Background
Special Article Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Vânia Tietsche de Moraes Hungria 1 Edvan de
More informationPATIENT HANDBOOK. Multiple Myeloma. Improving Lives Finding the Cure. Cancer of the Bone Marrow. Prepared by Brian G.M. Durie, M.D.
PATIENT HANDBOOK A Publication of the International Myeloma Foundation Dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure. Prepared by Brian G.M.
More informationA Focus on Multiple Myeloma
A Focus on Multiple Myeloma Guest Expert: Madhav Dhodapkar, MD Professor of Hematology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed and Dr.
More informationHow to treat elderly patients with multiple myeloma: combination of therapy or sequencing
MULTIPLE MYELOMA How to treat elderly patients with multiple myeloma: combination of therapy or sequencing Antonio Palumbo 1 and Francesca Gay 1 1 Divisione di Ematologia dell Università di Torino, Azienda
More informationWaldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP
Waldenström Macroglobulinemia: The Burning Questions IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Are my kids going to get this? Familial seen in approximately 5 10% of all CLL patients and can be associated
More informationMultiple Myeloma Something Old, Something New, Something Borrowed
Multiple Myeloma Something Old, Something New, Something Borrowed UCT Nicolas Novitzky Dip Med, PhD, FCP(SA) Haematology Clinical & Laboratory Science, Department of Medicine University of Cape Town 1.
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationFuture strategies for myeloma: An overview of novel treatments In development
Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide
More informationTable of Contents Accelerate Your Research Introduction I. From the Real World to the Lab II. Research Challenges III. How Can Conversant Bio Help?
Table of Contents Accelerate Your Research 2 Introduction 3 I. From the Real World to the Lab 4 A. Diagnosing Multiple Myeloma 4 1. Lab Tests 4 2. Bone Marrow Exams 6 3. Imaging Studies 7 B. Subtypes of
More informationGlossary of Multiple Myeloma Terms
Some things that make multiple myeloma (MM) difficult to understand are the unfamiliar medical terms that some experts and healthcare providers use to explain it. You may come across words like these when
More informationMyeloma. Anne Grace, myeloma survivor. Support for this publication provided by
Myeloma Anne Grace, myeloma survivor Support for this publication provided by Revised 2015 Publication Update Myeloma The Leukemia & Lymphoma Society wants you to have the most up-to-date information about
More informationUse of free light chain analysis in the diagnosis, prognosis and therapy of multiple myeloma. Amitabha Mazumder, MD
Use of free light chain analysis in the diagnosis, prognosis and therapy of multiple myeloma Amitabha Mazumder, MD Monoclonal Gammopathies Multiple Myeloma 18% Light Chain Dep Ds < 1% AL Amyloidosis 9%
More informationMomentum in Multiple Myeloma Treatment
WHITE PAPER Momentum in Multiple Myeloma Treatment Dr. Harish P. Dave, MD, MBA Dr. Ben Manderman, MD Quintiles examines promising new approaches to more effective multiple myeloma treatments. HIGH RESPONSE
More informationREVLIMID and IMNOVID for Multiple Myeloma
REVLIMID and IMNOVID for Multiple Myeloma What is Multiple Myeloma? Multiple myeloma (MM) is a persistent and life-threatening blood cancer that is characterised by tumour proliferation and immune suppression.
More informationChapter 8. Summary, general discussion and future perspectives
Summary, general discussion and future perspectives 115 Summary Multiple Myeloma (MM) is characterized by a malignant proliferation of monoclonal plasma cells in the bone marrow, clinical presenting by
More informationMultiple Myeloma Patient Handbook. www.myeloma.ca
Multiple Myeloma Patient Handbook www.myeloma.ca Introduction This resource has been designed for: 1. Someone who has been newly diagnosed with myeloma and is wondering what it means and what the future
More informationModern Induction Therapy for Transplant-ineligible Multiple Myeloma Patients: Literature of Review
Modern Induction Therapy for Transplant-ineligible Multiple Myeloma Patients: Literature of Review Dr. Kalita Lohit kumar 1, Dr. Gogoi Pabitra Kamar 2, Dr. Sarma Umesh Ch. 3 1 MS, Assistant Professor,
More informationRevving up the Revlimid Debate Lenalidomide as Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant
Revving up the Revlimid Debate Lenalidomide as Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant Sarah M. Villarreal, Pharm.D. PGY2 Hematology/Oncology Pharmacy Resident Department
More informationMyeloma. A guide for patients and families. 1800 620 420 leukaemia.org.au
Myeloma A guide for patients and families 1800 620 420 leukaemia.org.au Notes Contents Acknowledgments 4 Introduction 5 The Leukaemia Foundation 6 Blood cancers 10 What is myeloma? 16 Who gets myeloma?
More informationIntegrating novel agents into multiple myeloma treatment current status in Switzerland and treatment recommendations
current status in Switzerland and treatment recommendations Christian Taverna a, Mario Bargetzi b, Daniel Betticher c, Jürg Gmür d, Michael Gregor e, Dominik Heim f, Urs Hess g, Nicolas Ketterer h, Erika
More informationMultiple Myeloma How to Evaluate Response To Treatment and Relapse
Multiple Myeloma How to Evaluate Response To Treatment and Relapse D R L. G AR D E R E T Saint Antoine Hospital, Paris Haematology Department 1 What is Multiple Myeloma? 4 Diagnostic Tools 8 Response to
More informationUnderstanding Bisphosphonate Therapy
Understanding Bisphosphonate Therapy International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (United States and Canada) 818-487-7455 FAX:
More informationComparison of Serum Beta 2-Microglobulin and 24 hour Urinary Creatinine Clearance as a Prognostic Factor in Multiple Myeloma
J Korean Med Sci 2006; 21: 639-44 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences Comparison of Serum Beta 2-Microglobulin and 24 hour Urinary Creatinine Clearance as a Prognostic Factor
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationNATIONAL CANCER INSTITUTE. Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
NATIONAL CANCER INSTITUTE Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Basic Trial Information Phase Type Status Age Sponsor Protocol IDs Phase
More informationPlasma Cell Disorders
Plasma Cell Disorders 2015 Subtypes of Plasma Cell Disorders Increased Plasma Cells Monoclonal Gammopathy Myeloma Macroglobulinemia (IgM) Increased / Altered Products of Plasma Cells Light Chain Amyloidosis
More informationPro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany
Pro Cure in Multiple Myeloma Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Several hematological malignancies can be cured
More informationKharkov Regional Centre of Cardiovascular surgery V.N. Karazin Kharkov National University Department of Internal Medicine.
Kharkov Regional Centre of Cardiovascular surgery V.N. Karazin Kharkov National University Department of Internal Medicine Multiple Myeloma Associate professor Abduyeva F.M., MD, PhD 2014 Definition Multiple
More informationMultiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology Advance Access published August 16, 2013 Annals of Oncology 00: 1 5, 2013 doi:10.1093/annonc/mdt297 Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
More informationLeukemia (2009), 1 15 & 2009 Macmillan Publishers Limited All rights reserved 0887-6924/09 $32.00. www.nature.com/leu
REVIEW (2009), 1 15 & 2009 Macmillan Publishers Limited All rights reserved 0887-6924/09 $32.00 www.nature.com/leu for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy
More information2014; 5(3): 248-252. doi: 10.7150/jca.8541 Research Paper
248 Ivyspring International Publisher Journal of Cancer 2014; 5(3): 248-252. doi: 10.7150/jca.8541 Research Paper Partial Response at Completion of Bortezomib- Thalidomide-Dexamethasone (VTd) Induction
More informationClinical Course of Patients With Relapsed Multiple Myeloma. Mayo Clin Proc. July 2004;79(7):867-874 www.mayo.edu/proceedings 867
ORIGINAL RELAPSED MULTIPLE ARTICLE MYELOMA Clinical Course of Patients With Relapsed Multiple Myeloma SHAJI K. KUMAR, MD; TERRY M. THERNEAU, PHD; MORIE A. GERTZ, MD; MARTHA Q. LACY, MD; ANGELA DISPENZIERI,
More informationMultiple Myeloma: Overview and Therapeutic Approaches
Multiple Myeloma: Overview and Therapeutic Approaches Presented as a Live Webinar Wednesday, August 14, 2013 and Wednesday, September 11, 2013 Planned and conducted by ASHP Advantage and supported by educational
More informationADVANCES IN MULTIPLE MYELOMA:
MYELOMA AND THE NEWLY DIAGNOSED PATIENT: A FOCUS ON TREATMENT AND MANAGEMENT S. Vincent Rajkumar, MD LEARNING OBJECTIVES Upon completion of this educational activity, participants should be able to: Discuss
More informationORIGINAL ARTICLE. European Journal of Haematology ISSN 0902-4441
European Journal of Haematology ISSN 0902-4441 ORIGINAL ARTICLE Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory
More informationFundamentals in the Management of Multiple Myeloma
CONTINUING MEDICAL EDUCATION Fundamentals in the Management of Multiple Myeloma S A W Fadilah, MMed (Int Med), FRCPE Department of Medicine & Cell Therapy Center, Faculty of Medicine, Universiti Kebangsaan
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY Torben Plesner, Henk Lokhorst, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson
More informationContinuing medical education activity in American Journal of Hematology
Continuing medical education activity in American Journal of Hematology CME Editor: Ayalew Tefferi, MD Author: S. Vincent Rajkumar, MD Article Title: Multiple Myeloma: 2012 update on Diagnosis, Risk-stratification
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More information